Cargando…

How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world

As underlined in the minireview by Blomstrand et al, given the poor prognosis and the paucity of data on a therapeutic sequence in pancreatic ductal adenocarcinoma (PDAC), additional randomized controlled trials and real-world evidence studies addressing current and novel regimens are needed. The re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pretta, Andrea, Spanu, Dario, Mariani, Stefano, Liscia, Nicole, Ziranu, Pina, Pusceddu, Valeria, Puzzoni, Marco, Massa, Elena, Scartozzi, Mario, Lai, Eleonora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153079/ https://www.ncbi.nlm.nih.gov/pubmed/35662988 http://dx.doi.org/10.5306/wjco.v13.i5.417

Ejemplares similares

Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?
por: Pretta, Andrea, et al.
Publicado: (2022)

Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
por: Spanu, Dario, et al.
Publicado: (2022)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
por: Mariani, Stefano, et al.
Publicado: (2022)

New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression
por: Ziranu, Pina, et al.
Publicado: (2023)

Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
por: Lai, Eleonora, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors
por: Ziranu, Pina, et al.
Publicado: (2023)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
por: Procaccio, Letizia, et al.
Publicado: (2023)

Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression
por: Vega-Benedetti, Ana Florencia, et al.
Publicado: (2020)

The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review
por: Massa, Elena, et al.
Publicado: (2021)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

Real-Life Results of Palliative Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
por: Varzaru, Bianca, et al.
Publicado: (2023)

Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
por: Elias, Rawad, et al.
Publicado: (2022)

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
por: Houg, Demi S., et al.
Publicado: (2018)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue
por: Vega-Benedetti, Ana Florencia, et al.
Publicado: (2021)

Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers
por: Zhang, Ruyi, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
por: Gautam, Shailendra K., et al.
Publicado: (2023)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
por: Bengtsson, Axel, et al.
Publicado: (2020)

From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy
por: Giampieri, Riccardo, et al.
Publicado: (2020)

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
por: George, Ben, et al.
Publicado: (2021)

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
por: Taieb, Julien, et al.
Publicado: (2023)

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

Estimating Metastatic Risk of Pancreatic Ductal Adenocarcinoma at Single-Cell Resolution
por: Chen, Sina, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma in colonic wall: metastatic disease or cancerized pancreatic ectopic tissue?
por: Gallo, Graziana, et al.
Publicado: (2020)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
por: Madeddu, Clelia, et al.
Publicado: (2022)

CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma
por: Teodorczyk, M, et al.
Publicado: (2015)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma
por: Grogan, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l55eshjb1j1i4h5a70k3d9et94